Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in pyoderma gangrenosum
NCT07444684Phase 2Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in pyoderma gangrenosum (PG), sponsored by Hengrui Therapeutics. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SHR-1139
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT07444684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444684.